First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study

被引：0

作者：

Wang, Michael L. ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Eckert, Karl ^{[3
]}

Lin, Jennifer ^{[3
]}

Neuenburg, Jutta ^{[3
]}

Tam, Constantine ^{[4
,5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Maria Sklodowska Curie Natl Inst Oncol, Krakow, Poland

[3] Pharmacyclics LLC, Sunnyvale, CA USA

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] St Vincents Hosp, Melbourne, Vic, Australia

来源：

关键词：

MCL; mantle cell lymphoma; TP53; ibrutinib; venetoclax;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-129

引用

页码：S259 / S259

页数：1